Search research articles
Contact Us
Filters
Showing results (181-190 of 492) with videos related to
Page
of 50
Sort By:
Cancer Chemotherapy and Pharmacology
|
August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
Paul Haluska, Frank Worden, David Olmos, et al.
The Prostate
|
June 23, 2009
A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies
Gerhardt Attard, Sian Rizzo, Ioanna Ledaki, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
L R Molife, S Alam, D Olmos, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
European Urology
|
April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
European Urology
|
April 28, 2016
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
Jonathan Welti, Daniel Nava Rodrigues, Adam Sharp, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2011
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K Fizazi, J S De Bono, A Flechon, et al.
Page
of 50
Search research articles
Search
Showing results (181-190 of 492) with videos related to
Sort By:
Page
of 50
Cancer Chemotherapy and Pharmacology
|
August 4, 2009
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
Paul Haluska, Frank Worden, David Olmos, et al.
The Prostate
|
June 23, 2009
A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies
Gerhardt Attard, Sian Rizzo, Ioanna Ledaki, et al.
British Journal of Cancer
|
November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
G Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience
L R Molife, S Alam, D Olmos, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
Cancer Chemotherapy and Pharmacology
|
September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
J Mateo, J Berlin, J S de Bono, et al.
European Urology
|
April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
European Urology
|
April 28, 2016
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
Jonathan Welti, Daniel Nava Rodrigues, Adam Sharp, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2011
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K Fizazi, J S De Bono, A Flechon, et al.
Page
of 50